(VIANEWS) – VISTIN PHARMA (VISTN.OL) is among this list of stock assets with the highest dividend rate and return on equity on the Healthcare sector.
| Financial Asset | Price | Forward Dividend Yield | Return on Equity |
|---|---|---|---|
| VISTIN PHARMA (VISTN.OL) | kr26.90 | 7.29% | 23.89% |
| EUROFINS SCIENT. (ERF.PA) | €59.08 | 0.95% | 7.27% |
| SARTORIUS STED BIO (DIM.PA) | €264.30 | 0.37% | 5.31% |
Several Euronext companies pay out dividends to its shareholders. The dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.
1. VISTIN PHARMA (VISTN.OL)
7.29% Forward Dividend Yield and 23.89% Return On Equity
Vistin Pharma ASA, through its subsidiary, Vistin Pharma AS, produces and sells active pharmaceutical ingredients (APIs) worldwide. It offers metformin HCl APIs and direct compressive granulates for the pharmaceutical industry. Vistin Pharma ASA was founded in 1969 and is headquartered in Oslo, Norway.
Earnings Per Share
As for profitability, VISTIN PHARMA has a trailing twelve months EPS of kr1.54.
PE Ratio
VISTIN PHARMA has a trailing twelve months price to earnings ratio of 17.47. Meaning, the purchaser of the share is investing kr17.47 for every norwegian krone of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 23.89%.
Yearly Top and Bottom Value
VISTIN PHARMA’s stock is valued at kr26.90 at 07:30 EST, higher than its 52-week high of kr24.90.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, VISTIN PHARMA’s stock is considered to be oversold (<=20).
More news about VISTIN PHARMA.
2. EUROFINS SCIENT. (ERF.PA)
0.95% Forward Dividend Yield and 7.27% Return On Equity
Eurofins Scientific SE, together with its subsidiaries, provides various analytical testing and laboratory services worldwide. The company offers a portfolio of various analytical methods and tests to evaluate the safety, identity, composition, authenticity, origin, traceability, and purity of various products. It provides services such as agroscience, including biological assessment, consumer and human, and environmental safety, product chemistry, regulatory consultancy, and seed services; agro testing; assurance, such as product inspection, auditing, certification, training and consultation of food, consumer products, healthcare and cosmetics, and food supplements; biopharma, and clinical diagnostics. In addition, the company offers consumer product testing, which include sustainability, expert services and regulatory, consumer research and sensory evaluation, audits, testing, certifications and approvals, inspections, and training courses for various industries; cosmetics and personal care; environment testing, including water, air, soil, waste, and other products testing; and food and feed testing that include allergen, GMO, grain, meat, nano material, pesticides, and residual DNA testing. Further, it offers audit and certification, training and consulting; food irradiation and labelling, heavy metals, carbohydrates, radioactivity, nutritional analysis, microbiolody, and testing for persistent organic pollutants, veterinary drug residue, dioxins and organic contaminants, pesticides, mycotoxins, and vitamins, as well as analyses for genetic modifications. Additionally, the company provides forensic, genomic, maritime, materials and engineering, REACH, and other services. The company was founded in 1987 and is headquartered in Luxembourg City, Luxembourg.
Earnings Per Share
As for profitability, EUROFINS SCIENT. has a trailing twelve months EPS of €1.57.
PE Ratio
EUROFINS SCIENT. has a trailing twelve months price to earnings ratio of 37.63. Meaning, the purchaser of the share is investing €37.63 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 7.27%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 6.5%, now sitting on 6.72B for the twelve trailing months.
Yearly Top and Bottom Value
EUROFINS SCIENT.’s stock is valued at €59.08 at 07:30 EST, below its 52-week high of €62.10 and way higher than its 52-week low of €39.47.
Moving Average
EUROFINS SCIENT.’s value is way above its 50-day moving average of €51.47 and above its 200-day moving average of €54.96.
More news about EUROFINS SCIENT..
3. SARTORIUS STED BIO (DIM.PA)
0.37% Forward Dividend Yield and 5.31% Return On Equity
Sartorius Stedim Biotech S.A. engages in the production and sale of instruments and consumables for the biopharmaceutical industry worldwide. The company offers various products, such as cell lines; cell culture media; bioreactors; advanced therapies; and a range of products for separation, purification, and concentration processes, as well as products and systems for storage and transportation of intermediate and finished biological products. It also provides cell cultivation, fermentation, separation, purification, and fluid management services; biolayer interferometry instruments; microbiology enumeration, sterility testing, and air monitoring instruments; pipette products; sensors and analyzers; biomolecule analysis tools; flow cytometry; batch and intensified chromatography systems; lab data and fleet management software; live cell imaging and analysis; surface plasmon resonance solutions; and weighing products. In addition, the company offers data analytics software for modeling and optimizing processes of biopharmaceutical development and production; process automation platform and software; and develops and produces transfection, as well as other DNA/RNA delivery reagents and plasmid DNA. It serves manufacturers of medications, vaccines, foods, and chemicals, as well as research and development laboratories. The company was incorporated in 1978 and is headquartered in Aubagne, France. As of December 31, 2023, Sartorius Stedim Biotech S.A. operates as a subsidiary of Sartorius AG.
Earnings Per Share
As for profitability, SARTORIUS STED BIO has a trailing twelve months EPS of €3.36.
PE Ratio
SARTORIUS STED BIO has a trailing twelve months price to earnings ratio of 78.66. Meaning, the purchaser of the share is investing €78.66 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 5.31%.
Moving Average
SARTORIUS STED BIO’s value is way above its 50-day moving average of €173.33 and way higher than its 200-day moving average of €211.18.
More news about SARTORIUS STED BIO.
